[go: up one dir, main page]

LT3468621T - Šerdinis aneksinų domenas ir jo panaudojimas antigeno pristatymui ir vakcinavimui - Google Patents

Šerdinis aneksinų domenas ir jo panaudojimas antigeno pristatymui ir vakcinavimui

Info

Publication number
LT3468621T
LT3468621T LTEPPCT/EP2017/063985T LTEP2017063985T LT3468621T LT 3468621 T LT3468621 T LT 3468621T LT EP2017063985 T LTEP2017063985 T LT EP2017063985T LT 3468621 T LT3468621 T LT 3468621T
Authority
LT
Lithuania
Prior art keywords
annexins
vaccination
core domain
antigen delivery
antigen
Prior art date
Application number
LTEPPCT/EP2017/063985T
Other languages
English (en)
Inventor
Fatmire BUJUPI
Peter Krammer
Heiko Weyd
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Publication of LT3468621T publication Critical patent/LT3468621T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/EP2017/063985T 2016-06-10 2017-06-08 Šerdinis aneksinų domenas ir jo panaudojimas antigeno pristatymui ir vakcinavimui LT3468621T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16173925 2016-06-10
PCT/EP2017/063985 WO2017211964A1 (en) 2016-06-10 2017-06-08 The core domain of annexins and uses thereof in antigen delivery and vaccination

Publications (1)

Publication Number Publication Date
LT3468621T true LT3468621T (lt) 2022-12-27

Family

ID=56148135

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/063985T LT3468621T (lt) 2016-06-10 2017-06-08 Šerdinis aneksinų domenas ir jo panaudojimas antigeno pristatymui ir vakcinavimui

Country Status (15)

Country Link
US (2) US10947283B2 (lt)
EP (1) EP3468621B1 (lt)
JP (1) JP7377604B2 (lt)
CN (2) CN121086057A (lt)
CA (1) CA3027011A1 (lt)
DK (1) DK3468621T3 (lt)
ES (1) ES2933825T3 (lt)
FI (1) FI3468621T3 (lt)
HR (1) HRP20221372T1 (lt)
HU (1) HUE060537T2 (lt)
LT (1) LT3468621T (lt)
PL (1) PL3468621T3 (lt)
PT (1) PT3468621T (lt)
SI (1) SI3468621T1 (lt)
WO (1) WO2017211964A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3692984A1 (en) 2019-02-08 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Annexin-coated particles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506056A (ja) 1999-08-05 2003-02-18 ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン 腫瘍抑制遺伝子anx7のノックアウトマウス
DE60015392D1 (de) 1999-12-29 2004-12-02 Glaxo Group Ltd Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
DE60124927T2 (de) 2000-09-01 2007-09-20 Philadelphia Health And Education Corp. Verfahren und zusammensetzungen zur inhibition der angiogenese
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
NZ579262A (en) 2007-02-23 2012-04-27 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2009049892A1 (en) 2007-10-17 2009-04-23 European Molecular Biology Laboratory (Embl) Polypeptides comprising an annexin core domain, compositions, methods and use thereof
US8052970B2 (en) * 2008-06-30 2011-11-08 The Regents Of The University Of Michigan Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
US9610359B2 (en) * 2009-12-23 2017-04-04 Burnham Institute For Medical Research Methods and compositions related to annexin 1-binding compounds
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9555074B2 (en) * 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
JP2014095643A (ja) 2012-11-11 2014-05-22 Nagoya City Univ 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
JPWO2014126127A1 (ja) 2013-02-13 2017-02-02 国立大学法人北海道大学 ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法
ES2928331T3 (es) * 2013-11-13 2022-11-17 Univ Minnesota Composiciones de variantes de anexina II y métodos
EP3045470A1 (en) * 2015-01-15 2016-07-20 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy

Also Published As

Publication number Publication date
SI3468621T1 (sl) 2023-01-31
HUE060537T2 (hu) 2023-03-28
HRP20221372T1 (hr) 2023-01-06
WO2017211964A1 (en) 2017-12-14
DK3468621T3 (da) 2022-12-05
CA3027011A1 (en) 2017-12-14
PT3468621T (pt) 2022-12-21
PL3468621T3 (pl) 2023-01-30
EP3468621A1 (en) 2019-04-17
CN121086057A (zh) 2025-12-09
EP3468621B1 (en) 2022-09-21
US20190144513A1 (en) 2019-05-16
JP2019517271A (ja) 2019-06-24
FI3468621T3 (fi) 2023-01-13
US10947283B2 (en) 2021-03-16
JP7377604B2 (ja) 2023-11-10
ES2933825T3 (es) 2023-02-14
US20210230238A1 (en) 2021-07-29
US11851463B2 (en) 2023-12-26
CN109328077A (zh) 2019-02-12

Similar Documents

Publication Publication Date Title
IL284348A (en) Hiv pre-immunization and immunotherapy
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
IL254068A0 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
EP3256156C0 (en) IMMUNOTHERAPY VACCINE AND ANTIBODY-BASED COMBINATION THERAPY
IL263657A (en) Anti-c5 antibodies and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
LT3295951T (lt) Anti-pvrig antikūnai ir naudojimo būdai
IL252646B (en) Antibodies targeting g-protein coupled receptor and methods of use
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
IL258121A (en) Anti-pro/latent-myostatin antibodies and uses thereof
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
IL240472A0 (en) Chimeric antigen receptor and methods of use thereof
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
BR112017023153A2 (pt) dispositivo de acoplamento magnético e métodos para uso com o mesmo
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
DK3169703T3 (da) Kimær antigenreceptor og anvendelse deraf
LT3618928T (lt) Anti-sortilino antikūnai ir jų panaudojimo būdai
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
BR112016020889A2 (pt) variantes de hppd e métodos de uso
DK3233903T3 (da) Kimære antigenreceptorer og anvendelsesfremgangsmåder